Enteris BioPharma, Inc, a biotechnology company, announced that Cara Therapeutics has successfully initiated a Phase One clinical trial of its oral formulation of CR845/difelikefalin (Korsuva) in patients with chronic liver disease (CLD). The oral tablet formulation of Korsuva was engineered using Enteris’ proprietary oral peptide and small molecule delivery technology, Peptelligence. The oral Korsuva Phase One initiation marks the fourth…